|Videos|December 5, 2022

Dr. Laura Sena discusses ongoing trials of bipolar androgen therapy in prostate cancer

Author(s)Urology Times staff

Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.

In an interview during the SUO 2023 Annual Meeting, Laura Anne Sena, MD, PhD, highlighted ongoing trials exploring bipolar androgen therapy for the treatment of patients with prostate cancer. Sena is an instructor of oncology at Johns Hopkins Medicine.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

ESMO 2026: Key presentations across genitourinary oncology

October 20th, 2026

ESMO 2026: Key presentations across genitourinary oncology

Take a look through some of the notable data presentations at this year's ESMO Congress.

Trending on Urology Times

How PSMA-PET shapes staging and recurrence workup in prostate cancer

ESMO 2026: Key presentations across genitourinary oncology

Engy Habashy, MD, on the role of androgens in GSM management

European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC

Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC